Claims
- 1. A method of treating abnormal renal function caused by abnormal levels of neuropeptide Y (NPY) comprising administering to a human or an animal in need thereof an effective amount of a pharmaceutical composition comprising at least one specific isomer of inositol triphosphate sufficient to treat abnormal renal function caused by abnormal levels of neuropeptide Y.
- 2. A method of treating abnormal renal function comprising administering to a human or an animal in need thereof an effective amount of a pharmaceutical composition comprising at least one specific isomer of inositol triphosphate sufficient to treat abnormal renal function caused by abnormal levels of neuropeptide Y.
- 3. A method according to claims 1 or 2 wherein the pharmaceutical composition comprises an inositoltriphosphate in salt form.
- 4. A method according to claim 3 wherein the salt of inositoltriphosphate is a salt of sodium, potassium, calcium or zinc.
- 5. A method according to claims 1 or 2 wherein the pharmaceutical composition is in tablet or granulated form.
- 6. A method according to claims 1 or 2 wherein the pharmaceutical composition is in the form of a solution.
- 7. A method according to claim 6 wherein the pharmaceutical composition comprises at least one isomer of inositoltrisphosphate selected from the group D-myo-inositol-1.2.6-trisphosphate, myo-inositol-1.2.3-trisphosphate and L-myo-inositol-1.3.4-trisphosphate.
- 8. A method of treating renal diseases by administering to a human or an animal a pharmaceutical composition comprising an effective amount of at least one isomer of inositoltrisphosphate and another pharmaceutically active compound effective in the renal area sufficient to obtain said treatment.
- 9. A method according to claim 8 wherein the composition is in a combined dosage form.
- 10. A method according to claim 8 wherein the composition is in a separate dosage form for separate or combined administration.
- 11. A method according to claim 8 wherein the isomer of inositoltriphosphate is D-myo-inositol-1.2.6-triphosphate.
Priority Claims (2)
Number |
Date |
Country |
Kind |
8405295 |
Oct 1984 |
SEX |
|
8601709 |
Dec 1986 |
SEX |
|
REFERENCE TO RELATED APPLICATIONS
This is a continuation-in-part of U.S. patent application, Ser. No. 580,661 filed Sep. 11, 1990, now U.S. Pat. No. 5,128,332, which is a continuation-in-part of U.S. patent application, Ser. No. 492,740, filed Mar. 13, 1990, now U.S. Pat. No. 5,015,634, which is a continuation-in-part of U.S. patent application, Ser. No. 367,968, filed Jun. 19, 1989, now U.S. Pat. No. 5,051,411, which is a continuation-in-part of U.S. patent application, Ser. No. 251,566, which is a continuation-in-part filed Sep. 30, 1988, now U.S. Pat. No. 5,023,248; U.S. patent application, Ser. No. 214,500 filed Jul. 1, 1988, now U.S. Pat. No. 5,003,098; which is a continuation-in-part of U.S. patent application, Ser. No. 173,985 filed Mar. 28, 1988, now U.S. Pat. No. 5,019,566; which is a continuation-in-part of U.S. patent application Ser. No. 038,230, filed Apr. 14, 1987, now abandoned, which is a continuation-in-part of U.S. patent application Ser. No. 15,679, filed Feb. 17, 1987 now U.S. Pat. No. 4,797,390, which is a continuation-in-part of U.S. patent application Ser. No. 788,801, filed Oct. 18, 1985 now U.S. Pat. No. 4,735,936.
Foreign Referenced Citations (2)
Number |
Date |
Country |
0179439 |
Oct 1985 |
EPX |
0359257 |
Sep 1989 |
EPX |
Continuation in Parts (9)
|
Number |
Date |
Country |
Parent |
580661 |
Sep 1990 |
|
Parent |
492740 |
Mar 1990 |
|
Parent |
367968 |
Jun 1989 |
|
Parent |
251566 |
Sep 1988 |
|
Parent |
214500 |
Jul 1988 |
|
Parent |
173985 |
Mar 1988 |
|
Parent |
38230 |
Apr 1987 |
|
Parent |
15679 |
Feb 1987 |
|
Parent |
788801 |
Oct 1985 |
|